1794-1795 / 2437
Treatment Phase
Follow-up Phase
Screening/Randomization Phase
Treatment until:
•
Confirmed progression
•
Unacceptable toxicity
•
Discontinuation due to
other reason
Follow-up:
•
Safety for ≥ 100 days
•
Progression
•
Survival every 3 months
Patients (N = 369)
•
First recurrence of GBM
•
Prior 1L treatment with at least
RT and TMZ
Nivolumab 3 mg/kg Q2W
n = 184
Bevacizumab 10 mg/kg Q2W
n = 185
Randomized 1:1
•
Stratified by
measurable disease
at baseline (yes/no)
CheckMate 143
Randomized phase III trial